ALT Altimmune Inc
Price (delayed)
$7.1
Market cap
$504.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$447.43M
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™),
Highlights
ALT's quick ratio is down by 32% QoQ and by 22% YoY
Altimmune's net income has decreased by 25% YoY and by 9% QoQ
Key stats
What are the main financial stats of ALT
Market
Valuations
Earnings
Shares outstanding
71.07M
Market cap
$504.6M
Enterprise value
$447.43M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.3
Price to sales (P/S)
1,231.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,093.97
Revenue
$409,000
EBIT
-$101.31M
EBITDA
-$99.81M
Free cash flow
-$71.49M
Per share
Balance sheet
Liquidity
EPS
-$1.64
Free cash flow per share
-$1.01
Book value per share
$2.15
Revenue per share
$0.01
TBVPS
$2.44
Total assets
$173.35M
Total liabilities
$20.82M
Debt
$0
Equity
$152.53M
Working capital
$156.03M
Debt to equity
0
Current ratio
11.3
Quick ratio
10.91
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
-24,402.7%
Gross margin
100%
Net margin
-24,779%
Operating margin
-26,822%
Return on assets
-54.9%
Return on equity
-60.5%
Return on invested capital
-127.5%
Return on capital employed
-64%
Return on sales
-24,770.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALT stock price
How has the Altimmune stock price performed over time
Intraday
-0.98%
1 week
11.11%
1 month
14.15%
1 year
172.03%
YTD
-36.89%
QTD
6.77%
Financial performance
How have Altimmune's revenue and profit performed over time
Revenue
$409,000
Gross profit
$409,000
Operating income
-$109.7M
Net income
-$101.35M
Gross margin
100%
Net margin
-24,779%
Altimmune's net income has decreased by 25% YoY and by 9% QoQ
Altimmune's operating income has decreased by 25% YoY and by 9% from the previous quarter
The net margin has declined by 10% since the previous quarter
The operating margin has declined by 9% since the previous quarter
Growth
What is Altimmune's growth rate over time
Valuation
What is Altimmune stock price valuation
P/E
N/A
P/B
3.3
P/S
1,231.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,093.97
The P/B is 67% higher than the 5-year quarterly average of 2.0 and 19% higher than the last 4 quarters average of 2.8
The equity has declined by 12% since the previous quarter and by 9% year-on-year
ALT's P/S is 3.2% above its last 4 quarters average of 1204.3
Efficiency
How efficient is Altimmune business performance
ALT's ROA is down by 36% YoY and by 11% QoQ
The return on equity has declined by 35% year-on-year and by 12% since the previous quarter
Altimmune's return on sales has decreased by 10% QoQ
The company's return on invested capital rose by 6% QoQ and by 3.2% YoY
Dividends
What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Altimmune financials performed over time
The total liabilities is up by 35% since the previous quarter and by 33% year-on-year
Altimmune's current ratio has decreased by 32% from the previous quarter and by 24% YoY
The debt is 100% smaller than the equity
The equity has declined by 12% since the previous quarter and by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.